Haridah Alias1*, Kit Mun Tan2, Hutkemri Zulnaidi3, Pooi Fong Wong4, Li Ping Wong1,5,6*
1. Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
2. Department of Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
3. Department of Mathematics and Science Education, Faculty of Education, University Malaya, Kuala Lumpur, Malaysia
4. Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
5. Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, Fujian, China
6. Department of Medicine, College of Medicine, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
*Corresponding Authors: Haridah Alias.
ABSTRACT
INTRODUCTION: There has been extensive recent effort to identify potential drug candidates targeting cellular senescence to treat ageing-related comorbidities. Malaysia could particularly benefit from such therapies, given the country’s high burden of cardiovascular diseases (CVDs) as 1.7 million people are currently living with three major risk factors of CVDs; diabetes, hypertension, and high cholesterol. These risk factors can induce early vascular ageing (EVA) and eventually progress to CVD in young adults.
OBJECTIVE(S): This study aimed to investigate hypothetical acceptance of medication for EVA, and to assess the determinants that influence acceptance among Malaysians aged 18 to 50 years old.
MATERIALS & METHODS: An anonymous cross-sectional survey was conducted across Malaysia among 1607 respondents from September 2023 to May 2024. The determinants of medication for EVA acceptance (knowledge, attitudinal factors and lifestyle risk behaviours) were analysed using partial least-squares structural equation modelling (PLS-SEM).
RESULTS: The majority reported “probably yes” (24.7%), and 6.7% reported “definitely yes” regarding the acceptability of medication for EVA. The PLS-SEM revealed two strong significant predictors of medication for EVA acceptance: (1) sceptical attitude (β=-0.328, p < 0.0001) and (2) perceived future risk of EVA (β=0.299, p<0.0001). There was a negative association between acceptability with perceived high current risk of EVA (β=-0.161, p<0.0001) and more frequent physical activity (β=-0.115, p<0.0001). The model showed that higher level of daily stress (β=0.117, p=0.007), being diagnosed with chronic disease (β=0.114, p<0.0001), greater body weight (β=0.113, p=0.001) and more frequent of practicing healthy eating (β=0.092, p=0.002) had a significant direct association with medication for EVA acceptability. Of the demographic characteristics, income (β=-0.064, p=0.032) and educational level (β=0.058, p=0.031) were significantly associated with acceptability.
CONCLUSION: Overall, Malaysian young adults indicated low acceptance of medication for EVA. Interventions to reduce negative perceptions of new therapies and improve awareness about vascular ageing may enhance acceptance of medication for EVA.
KEYWORDS: Senotherapeutic, Early Vascular Ageing, Young Adults, Cardiovascular, Premature Ageing


